Given a question and a context passage, generate the answer having the word or phrase from the context passage. Here, the answer should be a shortest continous span from the passage.

Q: Context: Sir Balan le Savage, brother of Sir Balin from Northumberland, is a minor character mentioned in various Arthurian legends. 
 Question: Who was the brother of Sir Balan?

A: sir balin
****
Q: Context: The smallest front of the war was in Catalonia. In 1689 the Duke of Noailles had led French forces there aimed at bringing further pressure to bear on the Spanish by re-igniting a peasant rising against Charles II, which initially broke out in 1687. Exploiting the situation, Noailles captured Camprodon on 22 May, but a larger Spanish army under the Duke of Villahermosa forced him to withdraw back to Roussillon in August. The Catalan campaign settled down in 1690, but a new front in Piedmont-Savoy proved more eventful. A ferment of religious animosities and Savoyard hatred of the French produced a theatre characterised by massacres and atrocities: constant guerrilla attacks by the armed populace were met by draconian reprisals. In 1690 Saint-Ruth took most of the Victor Amadeus II's exposed Duchy of Savoy, routing the Savoyard army in the process until only the great fortress of Montmelian remained in ducal hands; while to the south in Piedmont, Nicolas Catinat led 12,000 men and soundly defeated Victor Amadeus at the Battle of Staffarda on 18 August. Catinat immediately took Saluzzo, followed by Savigliano, Fossano, and Susa, but lacking sufficient troops, and with sickness rife within his army, Catinat was obliged to withdraw back across the Alps for the winter. 
 Question: What happened first: Catalan campaign settled down or the Battle of Staffarda?

A: catalan campaign settled down
****
Q: Context: Spleen tyrosine kinase (SYK) has come into focus as a potential therapeutic target in chronic inflammatory diseases, such as rheumatoid arthritis and asthma, as well as in B-cell lymphomas. SYK has also been involved in the signaling of immunoreceptors, cytokine receptors, and integrins. We therefore hypothesized that inhibition of SYK attenuates the inflammatory process underlying atherosclerosis and reduces plaque development. Low-density lipoprotein receptor-deficient mice consuming a high-cholesterol diet supplemented with 2 doses of the orally available SYK inhibitor fostamatinib for 16 weeks showed a dose-dependent reduction in atherosclerotic lesion size by up to 596% compared with the respective controls. Lesions of fostamatinib-treated animals contained fewer macrophages but more smooth muscle cells and collagen-characteristics associated with more stable plaques in humans. Mechanistically, fostamatinib attenuated adhesion and migration of inflammatory cells and limited macrophage survival. Furthermore, fostamatinib normalized high-cholesterol diet -induced monocytosis and inflammatory gene expression. We present the novel finding that the SYK inhibitor fostamatinib attenuates atherogenesis in mice. Our data identify SYK inhibition as a potentially fruitful antiinflammatory therapeutic strategy in atherosclerosis. 
 Question: Which enzyme is inhibited by a drug fostamatinib?

A:
spleen tyrosine kinase
****
